真核表达人乳头瘤病毒16型L_1蛋白在检测宫颈癌患者相应抗体的应用

DETECTION OF HOMOLOGOUS ANTIBODY BY EUKARYOTICEXPRESSIVE HPV_(16)L_1 PROTEIN IN SERUM AND VAGINALSECRETION OF PATIENTS WITH CERVICAL CANCER

用真核表达HPV16L1蛋白为抗原，酶联免疫吸附测定64例宫颈癌患者血清和阴道分泌物的相应抗体，并用型特异性聚合酶键反应检测宫颈癌组织HPV16L1基因。结果：宫颈癌组血清HPV16L1抗体阳性年64．1％，对照组20．8％；宫颈癌组阴道分泌物HPV16L1抗体阳性率64.1％，对照组25％；宫颈癌组HPV16L1基因检出率为42．2％，对照组10％。有显著差异（P＜0．01）。结论：高危型HPV感染，宫颈癌患者有明显免疫反应，全身和局部无明显差异，真核表达HPV16L1蛋白可用于宫颈癌患者的抗体测定。

Object: To investigate body immunoreaction of cervical cancer patients after being infected with high risk HPV. Methods: Eukaryotic expressive HPV16 L1 protein was adopted to detectHPV16L1 antibody in serum and vaginal secretion of64 cases with cervical cancer by ELISA. HPV16 L1gene expression in cancer tissues was analysed bythe technique of type--specific PCR (TS-PCR). Results: HPV16 L1 antibody was positive in serum in64. 1% (41/64) patients while 20. 8% (5/24) in thecontrols,HPV16L1 antibody was found in vaginal secretion in 64. 1 % (41/64) patients while 25% (6/24)in the controls. There were 48. 4% (31/64) casesdemonstrated positive in both serum and vaginal secretion. HPV16L1 gene expression was detected in42. 2% (27/64 ) cervical cancer specimens while10% (2/20) in the controls. There was considerablyhigh rate of incidence and correlation was observedbetween serum and vaginal secretion antibody measurements by X2test of matched samples. Conclusions: High risk HPV infection,especially cervical cancer could induce obvious immunoreaction,with no significant difference between systematicand local immunoresponses. Eukaryotic expressiveHPVi.LI protein could be used in detecting antibodyin serum and vaginal secretion of patients with cervical cancer,and could facilitate early diagnosis andprovide a new immunological method for cervicalcancer.